Skip to main navigation Skip to search Skip to main content

Consequences of switching from a fixed 2:1 ratio of amoxicillin/clavulanate (CLSI) to a fixed concentration of clavulanate (EUCAST) for susceptibility testing of Escherichia coli

  • Maurine A. Leverstein-van Hall*
  • , Karola Waar
  • , Jan Muilwijk
  • , ISIS-AR study group
  • , James Cohen Stuart
  • , L. J.M. Sabbeon
  • , H. M.E. Frenay
  • , B. Maraha
  • , P. H.J. van Keulen
  • , J. A.J.W. Kluytmans
  • , B. M. de Jongh
  • , B. J.M. Vlaminckx
  • , E. I.G.B. De Brauwer
  • , F. S. Stals
  • , L. J. Bakker
  • , J. W. Dorigo-Zetsma
  • , F. W. Sebens
  • , E. E. Mattsson
  • , J. A. Kaan
  • , S. F.T. Thijsen
  • A. G.M. Buiting, R. G.F. Wintermans, B. C. van Hees, R. W. Brimicombe, G. J.H.M. Ruijs, M. J. Wolfhagen, J. H. vanZeijl, K. Waar, N. H.M. Renders, A. T. Bernards, R. G.F. Wintermans, F. G.C. Heilmann, T. Halaby, B. P. Overbeek, J. F.P. Schellekens, C. L. Jansen, F. Vlaspolder, J. Alblas, A. K. van der Bij, T. Leenstra, M. A. Leverstein-van Hall*, J. Monen, J. Muilwijk, H. T. Tjhie, P. D.J. Sturm, B. M. Diederen, A. A. van Zwet, M. P.D. Deege, C. H.E. Boel, J. Cohen Stuart, B. G.A. Hendrickx
*Corresponding author for this work
  • National Institute of Public Health and the Environment
  • Haaglanden Medisch Centrum
  • Diaconessenhuis (Leiden)
  • Izore
  • Members of the ISIS-AR Study Group
  • Regional Public Health Laboratory Kennemerland
  • North West Hospital Group
  • Admiraal de Ruyter Hospital
  • Albert Schweitzer Ziekenhuis
  • St. Antonius Ziekenhuis
  • Zuyderland Medical Center (Heerlen)
  • Centraal Bacteriologisch en Serologisch Laboratorium (CBSL)
  • Deventer Ziekenhuis
  • Reinier de Graaf Groep
  • Diakonessenhuis Utrecht
  • ETZ Elisabeth
  • Franciscus Hospital (Roosendaal)
  • Gelre Ziekenhuizen
  • Haga Ziekenhuis
  • Isala Clinics
  • Leiden University
  • Lievensberg Hospital
  • Laboratory for Medical Microbiology and Public Health, Enschede
  • Laboratory for Infectious Diseases
  • Radboud University Medical Center
  • Rijnstate Hospital
  • SALTRO
  • Utrecht University
  • ZorgSaam Hospital

Research output: Contribution to journalArticleAcademicpeer-review

20 Citations (Scopus)
15 Downloads (Pure)

Abstract

Objectives: The CLSI recommends a fixed 2:1 ratio of co-amoxiclav for broth microdilution susceptibility testing of Enterobacteriaceae, while EUCASTrecommends a fixed 2 mg/L clavulanate concentration. The aims of this study were: (i) to determine the influence of a switch fromCLSI to EUCASTmethodology on Escherichia coli susceptibility rates; (ii) to compare susceptibility results obtained using EUCAST-compliant microdilution with those from disc diffusion and the Etest; and (iii) to evaluate the clinical outcome of patients with E. coli sepsis treated with co-amoxiclav in relation to the susceptibility results obtained using either method. Methods: Resistance rateswere determined in three laboratories that switched fromCLSI to EUCASTcards with the Phoenix system (Becton Dickinson) as well as in 17 laboratories that continued to use CLSI cards with the VITEK 2 system (bioMérieux). In one laboratory, isolateswere simultaneously tested by both the Phoenix system and either disc diffusion (n=471) or the Etest (n=113). Medical and laboratory records were reviewed for E. coli sepsis patients treated with co-amoxiclav monotherapy. Results: Only laboratories that switched methodology showed an increase in resistance rates - from19% in 2010 to 31% in 2011 (P,0.0001). All isolates that tested susceptible by microdilution were also susceptible by disc diffusion or the Etest, but of 326 isolates that tested resistant by microdilution, 43% and 59% tested susceptible by disc diffusion and the Etest, respectively. Among the 89 patients included there was a better correlation between clinical response and measured MICs using the Phoenix system than the Etest. Conclusions: EUCASTmethodology resulted in higherco-amoxiclav E. coli resistance rates than CLSI methodology, but correlated better with clinical outcome. EUCAST-compliant microdilution and disc diffusion provided discrepant results.

Original languageEnglish
Article numberdkt218
Pages (from-to)2636-2640
Number of pages5
JournalJournal of Antimicrobial Chemotherapy
Volume68
Issue number11
DOIs
Publication statusPublished - Nov 2013
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Consequences of switching from a fixed 2:1 ratio of amoxicillin/clavulanate (CLSI) to a fixed concentration of clavulanate (EUCAST) for susceptibility testing of Escherichia coli'. Together they form a unique fingerprint.

Cite this